Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Multiple Cleveland Clinic sites to participate in National Cancer Institute trial comparing treatment regimens for newly diagnosed patients
Dispelling myths and sharing practical experiences
Distinct molecular features found in five subtypes of disease
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Patients who relapse early after first-line chemotherapy are often, but not always, refractory to second-line chemotherapy
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Improving safety, efficacy and access for emerging therapies
Treatment may be a lifesaving option for patients with relapsed or refractory disease
Prospective study shows improved outcomes